Astellas Spent $3 Billion on a Gene Therapy. Now It's Trying Plan B.

ASP2957 is currently in a phase 1/2 open-label trial with enrollment underway. For the boys with XLMTM still waiting for a treatment, it represents the next realistic shot.

This Wasn't the Only Cut

Astellas didn't stop at gene therapy. The company also terminated two early-stage programs as part of a broader housecleaning:

• ASP5502: a STING inhibitor (a type of immune-modulating drug) being tested for Sjögren's syndrome
• ASP1570: a cancer candidate in a phase 1/2 solid tumor study

Both were killed for business reasons, not safety concerns. They simply didn't clear the bar anymore.

And these three cuts are just the visible tip. Astellas has terminated numerous clinical-stage programs as part of its R&D restructuring. That's not trimming the hedges; that's ripping out the garden and replanting.

Why Pharma Is Getting Ruthless With Pipelines

Astellas isn't alone here. The entire biopharma industry contracted for the first time in 30 years, with the global R&D pipeline dropping 3.9% from about 23,875 drugs at the start of 2025 to 22,940 at the start of 2026.

Roche narrowed its focus to just three core therapeutic areas. Pfizer trimmed from 271 to 257 programs. Novartis cut about 10% of its pipeline. Everyone is playing the same game: stop spreading resources thin across long-shot bets, and concentrate firepower on programs most likely to actually work.

For Astellas specifically, the math is urgent. Its blockbuster prostate cancer drug Xtandi faces patent cliffs after 2027. The company needs new revenue sources, and it can't afford to waste R&D dollars on programs with single-digit odds of success.

The New Astellas Playbook

CEO Naoki Okamura has laid out a three-phase plan running through 2034. The company is reorganizing around four "Primary Focus" areas: Cell and Gene Therapy, Vision Loss/Ophthalmology, Immuno-Oncology, and a new addition called Targeted Protein Degradation (essentially drugs that tag unwanted proteins for destruction by the cell's own recycling machinery).

R&D spending is set to increase significantly, with the company targeting a 30% R&D spending ratio by FY2027. That's a big number, and it signals that Astellas isn't cutting for austerity; it's cutting for precision. The company wants to be a sniper, not a shotgunner.

Does This Actually Work?

The honest answer: sometimes.

Pharma companies love to announce "strategic portfolio rationalization" (translation: we're killing the stuff that isn't working). The question is always whether the remaining programs are genuinely better, or whether the company is just rearranging deck chairs.

In Astellas' case, the AT132-to-ASP2957 swap has real scientific logic behind it. A 100-fold dose reduction isn't marketing spin; it's a meaningful safety improvement rooted in better capsid engineering. The preclinical data suggests Kate Therapeutics solved the targeting problem that doomed AT132.

But preclinical data is just a promissory note. The phase 1/2 trial will tell us whether ASP2957 delivers on that promise, or whether XLMTM continues to be one of biotech's most heartbreaking dead ends.

For the families waiting, Plan B needs to be better than Plan A. The science says it should be. Now Astellas has to prove it in actual patients.